Top

06-09-2018 | Cardiovascular disease | Article

Cardiovascular risk management in rheumatoid and psoriatic arthritis: online survey results from a national cohort study

Journal: BMC Rheumatology

Authors: Premarani Sinnathurai, Alexandra Capon, Rachelle Buchbinder, Vibhasha Chand, Lyndall Henderson, Marissa Lassere, Lyn March

Publisher: BioMed Central

Abstract

Background

Chronic inflammatory arthritis is associated with increased cardiovascular (CV) morbidity and mortality. Pharmacological management and healthy lifestyle modification is recommended to manage these risks, but it is not known how often these are utilised and whether there is any difference in their use between patients with different types of arthritis. The aim of this study was to determine and compare the proportion of participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) receiving pharmacological or lifestyle management strategies for CV risk factors. The secondary objective was to identify factors associated with use of management strategies.

Methods

A survey was sent to online participants in the Australian Rheumatology Association Database, a voluntary national registry for inflammatory arthritis. Participants were asked whether they took medications for hypertension, hyperlipidaemia and diabetes, and to report their height, weight, level of physical activity, and dietary changes made. The use of management strategies was compared between participants with RA and PsA. Logistic regression analyses were performed to identify factors associated with physical activity and dietary changes.

Results

There were 858 respondents with RA and 161 with PsA (response rate 64.5%). Pharmacological treatment was reported by 93% of participants with hypertension and 70% with hyperlipidaemia. All participants with diabetes reported being managed with dietary modification, pharmacological treatment, or a combination of both. Adequate physical activity was reported by 50.8%. Only 27% of overweight or obese participants reported making any dietary change for their health in the past year. There was no difference between RA and PsA in reported utilisation of management strategies. Hyperlipidaemia and being overweight were associated with making dietary change. Obesity and arthritis disease activity were negatively associated with physical activity.

Conclusions

Most participants with RA and PsA reported using pharmacological treatment for CV risk factors. Relatively few reported using lifestyle modifications. Targeted lifestyle interventions should be implemented for RA and PsA patients.

Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74:326–32.CrossRefPubMed

Boehncke W-H, Boehncke S. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep. 2012;14:343–8.CrossRefPubMed

Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690–7.CrossRefPubMed

Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis. 2010;69:1920–5.CrossRefPubMedPubMedCentral

Lacaille D, Avina-Zubieta JA, Sayre EC, Abrahamowicz M. Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population—closing the mortality gap. Ann Rheum Dis. 2017;76:1057–63.

Myasoedova E, Gabriel SE, Matteson EL, Davis JM, Therneau TM, Crowson CS. Decreased cardiovascular mortality in patients with incident rheumatoid arthritis (RA) in recent years: Dawn of a new era in cardiovascular disease in RA? J Rheumatol. 2017;44:732–9.

Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8:331–4.CrossRefPubMedPubMedCentral

Sharma A, Gopalakrishnan D, Kumar R, Vijayvergiya R, Dogra S. Metabolic syndrome in psoriatic arthritis patients: a cross-sectional study. Int J Rheum Dis. 2013;16:667–73.CrossRefPubMed

Pehlevan S, Yetkin DO, Bahadir C, Goktay F, Pehlevan Y, Kayatas K, et al. Increased prevalence of metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2014;12:43–8.CrossRefPubMed

10.

Han C, Robinson DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33:2167–72.PubMed

11.

Sinnathurai P, Lassere M, Buchbinder R, March L. Baseline characteristics of patients with psoriatic arthritis (PsA) from the Australian Rheumatology Association Database (ARAD) [abstract]. Intern Med J. 2015;45 Suppl 2:43.

12.

Labitigan M, Bahce-Altuntas A, Kremer JM, Reed G, Greenberg JD, Jordan N, et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:600–7.CrossRef

13.

Arumugam RAMA, McHugh NJ. Mortality and causes of death in psoriatic arthritis. J Rheumatol. 2012;89:32–5.

14.

Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72:211–6.CrossRefPubMed

15.

Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):12–29.CrossRefPubMed

16.

Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheumatol. 1997;40:1868–72.CrossRef

17.

Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong. China Arthritis Rheum. 2011;63:1182–9.CrossRefPubMed

18.

Ali Y, Tom BDM, Schentag CT, Farewell VT, Gladman DD. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum. 2007;56:2708–14.CrossRefPubMed

19.

Ogdie A, Haynes K, Troxel AB, Love TJ, Hennessy S, Choi H, et al. Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann Rheum Dis. 2014;73:149–53.CrossRefPubMed

20.

Buckley C, Cavill C, Taylor G, Kay H, Waldron N, Korendowych E, et al. Mortality in psoriatic arthritis - a single-center study from the UK. J Rheumatol. 2010;37:2141–4.CrossRefPubMed

21.

Peters MJL, Symmons DPM, McCarey D, Dijkmans BAC, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325–31.CrossRefPubMed

22.

Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJL, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2016;76:17.CrossRefPubMed

23.

Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for Research and Assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68:1060–71.PubMed

24.

Loza E, Lajas C, Andreu JL, Balsa A, González-Álvaro I, Illera O, et al. Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. Rheumatol Int. 2015;35:445–58.CrossRefPubMed

25.

Torre-Alonso JC, Carmona L, Moreno M, Galíndez E, Babío J, Zarco P, et al. Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain. Rheumatol Int. 2017;37:1239–48.CrossRefPubMed

26.

Castaneda S, Loza E, Dauden E, Carmona L. Consensus statement on the Management of Comorbidity in patients with rheumatoid arthritis and psoriasis. J Rheumatol. 2016;43:990–1.CrossRefPubMed

27.

National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. 2012. https://heartfoundation.org.au/images/uploads/publications/Absolute-CVD-Risk-Full-Guidelines.pdf. Accessed 18th Oct 2016.

28.

Buchbinder R, March L, Lassere M, Briggs AM, Portek I, Reid C, et al. Effect of treatment with biological agents for arthritis in Australia: the Australian rheumatology association database. Intern Med J. 2007;37:591–600.CrossRefPubMed

29.

World Health Organisation. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. In: WHO Technical Report Series. 2000. http://www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/. Accessed 18th Oct 2016.

30.

Work group recommendations: 2002 Exercise and Physical Activity Conference, St. Louis, Missouri. Session V: evidence of benefit of exercise and physical activity in arthritis. Arthritis Rheum. 2003;49:453–4.

31.

World Health Organisation. Global Recommendations on Physical Activity for Health. 2010. http://www.who.int/dietphysicalactivity/publications/9789241599979/en/. Accessed 18th Oct 2016.

32.

Zhang Z. Model building strategy for logistic regression: purposeful selection. Ann Transl Med. 2016;4:111.CrossRefPubMedPubMedCentral

33.

Gulati AM, Semb AG, Rollefstad S, Romundstad PR, Kavanaugh A, Gulati S, et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag health study. Ann Rheum Dis. 2015;75:819–24.

34.

Jafri K, Bartels CM, Shin D, Gelfand JM, Ogdie A. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: A population-based study. Arthritis Care Res (Hoboken). 2017;69:51–7.CrossRef

35.

Kohl HW 3rd, Craig CL, Lambert EV, Inoue S, Alkandari JR, Leetongin G, et al. The pandemic of physical inactivity: global action for public health. Lancet. 2012;380:294–305.CrossRefPubMed

36.

Langham S, Langham J, Goertz HP, Ratcliffe M. Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: a systematic and critical review. BMC Med Res Methodol. 2011;11:32.CrossRefPubMedPubMedCentral

37.

Centers for Disease Control and Prevention (CDC). Arthritis as a potential barrier to physical activity among adults with heart disease - United States, 2005 and 2007. MMWR Morb Mortal Wkly Rep. 2009;58:165–9.

38.

Centers for Disease Control and Prevention (CDC). Arthritis as a potential barrier to physical activity among adults with diabetes - United States, 2005 and 2007. MMWR Morb Mortal Wkly Rep. 2008;57:486–9.

39.

Hurkmans E, van der Giesen FJ, Vliet Vlieland TPM, Schoones J, Van den Ende ECHM. Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev. 2009:CD006853. https://doi.org/10.1002/14651858.CD006853.pub2.

40.

Abell J, Hootman J, Zack M, Moriarty D, Helmick C. Physical activity and health related quality of life among people with arthritis. J Epidemiol Community Health. 2005;59:380–5.CrossRefPubMedPubMedCentral

41.

Sokka T, Häkkinen A, Kautiainen H, Maillefert JF, Toloza S, Mørk Hansen T, et al. Physical inactivity in patients with rheumatoid arthritis: Data from twenty-one countries in a cross-sectional, international study. Arthritis Care Res (Hoboken). 2008;59:42–50.CrossRef

42.

Shih M, Hootman JM, Kruger J, Helmick CG. Physical activity in men and women with arthritis: National Health Interview Survey, 2002. Am J Prev Med. 2006;30:385–93.CrossRefPubMed

43.

Hootman JM, Macera CA, Ham SA, Helmick CG, Sniezek JE. Physical activity levels among the general US adult population and in adults with and without arthritis. Arthritis Care Res (Hoboken). 2003;49:129–35.CrossRef

44.

van den Oever IAM, Heslinga M, Griep EN, Griep-Wentink HRM, Schotsman R, Cambach W, et al. Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project. Rheumatology (Oxford). 2017;56:1472–8.CrossRef

45.

Der Ananian C, Wilcox S, Watkins K, Saunders R, Evans AE. Factors associated with exercise participation in adults with arthritis. J Aging Phys Act. 2008;16:125–43.CrossRefPubMed

46.

Wilcox S, Der Ananian C, Abbott J, Vrazel J, Ramsey C, Sharpe PA, et al. Perceived exercise barriers, enablers, and benefits among exercising and nonexercising adults with arthritis: Results from a qualitative study. Arthritis Care Res (Hoboken). 2006;55:616–27.CrossRef

47.

Baxter S, Smith C, Treharne G, Stebbings S, Hale L. What are the perceived barriers, facilitators and attitudes to exercise for women with rheumatoid arthritis? A qualitative study. Disabil Rehabil. 2016;38:773–80.

48.

Khoja SS, Almeida GJ, Chester Wasko M, Terhorst L, Piva SR. Association of light-intensity physical activity with lower cardiovascular disease risk burden in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:424–31.CrossRef

49.

Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2015;75:3.CrossRefPubMedPubMedCentral

50.

Gossec L, Coates LC, de Wit M, Kavanaugh A, Ramiro S, Mease PJ, et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol. 2016;12:743–50.CrossRefPubMed